See more : Taiwan Pelican Express Co., Ltd. (2642.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Otonomy, Inc. (OTIC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Otonomy, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Canadian Western Bank (CWB.TO) Income Statement Analysis – Financial Results
- Cronos Group Inc. (CRON.TO) Income Statement Analysis – Financial Results
- Kinross Gold Corporation (KGC) Income Statement Analysis – Financial Results
- Rollins, Inc. (ROL) Income Statement Analysis – Financial Results
- Kingspan Group plc (KGSPF) Income Statement Analysis – Financial Results
Otonomy, Inc. (OTIC)
About Otonomy, Inc.
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 125.00K | 273.00K | 600.00K | 745.00K | 1.24M | 683.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 370.00K | 1.19M | 912.00K | 946.00K | 3.10M | 1.66M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -245.00K | -915.00K | -312.00K | -201.00K | -1.86M | -981.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -196.00% | -335.16% | -52.00% | -26.98% | -150.65% | -143.63% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 34.67M | 28.00M | 32.81M | 31.84M | 42.70M | 60.72M | 38.76M | 31.80M | 16.34M | 8.52M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 49.78M | 23.21M | 7.84M | 3.51M | 2.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.71M | 14.58M | 11.69M | 20.01M | 46.84M | 49.78M | 23.21M | 7.84M | 3.51M | 2.41M |
| Other Expenses | 0.00 | -1.24M | 132.00K | 1.69M | 1.27M | 898.00K | 308.00K | -3.24M | -14.00K | 3.71M |
| Operating Expenses | 49.38M | 42.57M | 44.50M | 51.85M | 89.54M | 110.50M | 61.98M | 39.64M | 19.85M | 10.93M |
| Cost & Expenses | 49.75M | 43.76M | 45.41M | 52.80M | 92.64M | 112.16M | 61.98M | 39.64M | 19.85M | 10.93M |
| Interest Income | 43.00K | 326.00K | 1.72M | 1.69M | 1.27M | 899.00K | 419.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.60M | 1.57M | 1.59M | 4.00K | 0.00 | 0.00 | 0.00 | 39.00K | 2.53M | 444.00K |
| Depreciation & Amortization | 856.00K | 1.06M | 1.15M | 1.19M | 1.29M | 708.00K | 358.00K | 213.00K | 257.00K | 192.00K |
| EBITDA | -49.63M | -43.49M | -44.81M | -52.05M | -91.40M | -111.48M | -61.98M | -39.64M | -19.61M | -7.03M |
| EBITDA Ratio | -39,700.00% | -15,929.30% | -7,467.83% | -6,986.98% | -7,394.90% | -16,322.25% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -49.63M | -43.49M | -44.81M | -52.05M | -91.40M | -111.48M | -61.98M | -39.64M | -19.85M | -10.93M |
| Operating Income Ratio | -39,700.00% | -15,929.30% | -7,467.83% | -6,986.98% | -7,394.90% | -16,322.25% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.56M | -1.24M | 132.00K | 1.69M | 1.27M | 898.00K | 308.00K | -3.24M | 291.00K | 3.36M |
| Income Before Tax | -51.18M | -44.73M | -44.68M | -50.37M | -90.13M | -110.58M | -61.67M | -42.88M | -19.56M | -7.57M |
| Income Before Tax Ratio | -40,944.80% | -16,384.98% | -7,445.83% | -6,760.81% | -7,292.07% | -16,190.78% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -856.00K | -1.06M | -1.15M | -1.19M | -1.29M | -708.00K | -358.00K | -213.00K | 2.51M | 4.15M |
| Net Income | -50.33M | -43.67M | -43.53M | -49.18M | -88.84M | -110.58M | -61.67M | -42.88M | -19.56M | -7.57M |
| Net Income Ratio | -40,260.00% | -15,995.97% | -7,254.33% | -6,601.61% | -7,187.78% | -16,190.78% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.79 | -1.07 | -1.42 | -1.61 | -2.93 | -3.69 | -2.57 | -5.46 | -1.70 | -0.66 |
| EPS Diluted | -0.79 | -1.07 | -1.42 | -1.61 | -2.93 | -3.69 | -2.57 | -5.46 | -1.70 | -0.66 |
| Weighted Avg Shares Out | 63.44M | 40.85M | 30.73M | 30.61M | 30.30M | 29.96M | 23.95M | 7.85M | 11.47M | 11.47M |
| Weighted Avg Shares Out (Dil) | 63.44M | 40.85M | 30.73M | 30.61M | 30.30M | 29.96M | 23.95M | 7.85M | 11.47M | 11.47M |
The Daily Biotech Pulse: 2 IPOs, Nabriva Pneumonia Drug Gets Canadian Regulatory Nod, PhaseBio Doses First COVID-19 Trial Patient
The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
The Daily Biotech Pulse: Novavax Lands $1.6B For COVID-19 Vaccine, Amgen Prevails In Avastin Biosimilar Lawsuit, Cellectis Study Placed On Clinical Hold
Financial Analysis: INmune Bio (NASDAQ:INMB) and Applied Genetic Technologies (NASDAQ:AGTC)
The Daily Biotech Pulse: GlaxoSmithKline, IDEAYA Strike Oncology Partnership, Decision Day For Merck, Adverum's New CEO
Otonomy to Present at Raymond James 2020 Human Health Innovation Conference
Balancing Sars’s powers and duties with taxpayers’ rights and obligations
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
Source: https://incomestatements.info
Category: Stock Reports